The FDA has laid out a plan resembling the annual flu vaccine campaign, and the FDA's committee voted on one part of it. Here ...

In a unanimous 21-to-0 vote last week, an advisory board for the U.S. Food and Drug Administration (FDA) recommended that the ...

The U.S. Food and Drug Administration's key science advisory panel, the Vaccines and Related Biological Products Advisory ...

The expert panel voted on Thursday to recommend replacing the primary Covid-19 vaccine series with the BA.4/5 bivalent shot.

It's part of a plan to offer a single booster to the public each year that gives protection against the most recent, dominant ...

STAT's @helenbranswell and @matthewherper are tracking today's meeting of the Food and Drug Administration’s Vaccines and ...

In a recent briefing document published by the United States Food and Drug Administration (US-FDA) ahead of an advisory ...

In a document posted ahead of an advisory group meeting on Jan 26, the US Food and Drug Administration (FDA) today spelled ...

The advisory panel said that a single annual vaccine would be less confusing and more effective to health care workers and patients alike.

Future COVID-19 vaccines and boosters should be bivalent – meaning they’ll target older strains of the virus as well as the newer omicron BA.4 and BA.5 variants – following a unanimous recommendation ...

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet Thursday to discuss how to simplify ...

The Food and Drug Administration’s Vaccine Advisory Committee is meeting on Thursday to discuss the future of COVID-19 ...